相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Lindsay A. Becker et al.
NATURE (2017)
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Daniel R. Scoles et al.
NATURE (2017)
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
Sarah L. DeVos et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain
Nicole A. Datson et al.
PLOS ONE (2017)
Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells
James R. C. Miller et al.
SCIENTIFIC REPORTS (2017)
In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings
Benjamin Hall et al.
AGEING RESEARCH REVIEWS (2017)
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia
Megan S. Keiser et al.
HUMAN MOLECULAR GENETICS (2016)
Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels
Laura Rue et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment
Rumwald Leo G. Lecaros et al.
MOLECULAR THERAPY (2016)
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Benjamin E. Deverman et al.
NATURE BIOTECHNOLOGY (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
Suzan M. Hammond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis
Guohao Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Delivering a disease-modifying treatment for Huntington's disease
Bruno M. D. C. Godinho et al.
DRUG DISCOVERY TODAY (2015)
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients
Edward J. Wild et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Therapeutic genome editing: prospects and challenges
David Benjamin Turitz Cox et al.
NATURE MEDICINE (2015)
Onset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA
Richard Grondin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Alberto Lleo et al.
NATURE REVIEWS NEUROLOGY (2015)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Intrajugular Vein Delivery of AAV9-RNAi Prevents Neuropathological Changes and Weight Loss in Huntington's Disease Mice
Brett D. Dufour et al.
MOLECULAR THERAPY (2014)
Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?
Edward J. Wild et al.
MOVEMENT DISORDERS (2014)
Regulation of microRNA biogenesis
Minju Ha et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Huntington disease: natural history, biomarkers and prospects for therapeutics
Christopher A. Ross et al.
NATURE REVIEWS NEUROLOGY (2014)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
Biology of adeno-associated viral vectors in the central nervous system
Giridhar Murlidharan et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2014)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Kirupa Sathasivam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Thomas Gaj et al.
TRENDS IN BIOTECHNOLOGY (2013)
Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Vedell Louis Jeune et al.
HUMAN GENE THERAPY METHODS (2013)
SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
Leah Winer et al.
JAMA NEUROLOGY (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Richard Grondin et al.
BRAIN (2012)
Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
Dongbo Yu et al.
CELL (2012)
Single-Stranded siRNAs Activate RNAi in Animals
Walt F. Lima et al.
CELL (2012)
Widespread suppression of huntingtin with convection-enhanced delivery of siRNA
David K. Stiles et al.
EXPERIMENTAL NEUROLOGY (2012)
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2012)
MicroRNAs as putative mediators of treatment response in prostate cancer
Fardod O'Kelly et al.
NATURE REVIEWS UROLOGY (2012)
Huntingtin Holiday: Progress toward an Antisense Therapy for Huntington's Disease
Xiao-Hong Lu et al.
NEURON (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Mireia Garriga-Canut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits
Sofia Hult et al.
CELL METABOLISM (2011)
Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design
J. N. Martin et al.
GENE THERAPY (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2011)
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat
Keith T. Gagnon et al.
BIOCHEMISTRY (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sustained Effects of Nonallele-Specific Huntingtin Silencing
Valerie Drouet et al.
ANNALS OF NEUROLOGY (2009)
Allele-Selective Inhibition of Mutant Huntingtin by Peptide Nucleic Acid-Peptide Conjugates, Locked Nucleic Acid, and Small Interfering RNA
Jiaxin Hu et al.
OLIGONUCLEOTIDE THERAPEUTICS (2009)
Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine
Jiaxin Hua et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients
Edith L. Pfister et al.
CURRENT BIOLOGY (2009)
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference
Maria Stella Lombardi et al.
EXPERIMENTAL NEUROLOGY (2009)
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2009)
Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2009)
Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts
P. H. J. van Bilsen et al.
HUMAN GENE THERAPY (2008)
Delivery vehicles for small interfering RNA in vivo
Antonin R. De Fougerolles
HUMAN GENE THERAPY (2008)
Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
Eileen M. Denovan-Wright et al.
NEUROBIOLOGY OF DISEASE (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease
Melanie D. White et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
M. DiFiglia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Dirk Grimm et al.
NATURE (2006)
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
Y Machida et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Down-regulation of α-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model
H Hayashita-Kinoh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Adeno-associated virus serotypes: Vector toolkit for human gene therapy
Zhijian Wu et al.
MOLECULAR THERAPY (2006)
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
YL Wang et al.
NEUROSCIENCE RESEARCH (2005)
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice
E Rodriguez-Lebron et al.
MOLECULAR THERAPY (2005)
Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization
M Sioud
JOURNAL OF MOLECULAR BIOLOGY (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference
ZYJ Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
V Hornung et al.
NATURE MEDICINE (2005)
Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs
R Yi et al.
RNA (2005)
Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3
K Karikó et al.
JOURNAL OF IMMUNOLOGY (2004)
Activation of the interferon system by short-interfering RNAs
CA Sledz et al.
NATURE CELL BIOLOGY (2003)
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
I Dragatsis et al.
NATURE GENETICS (2000)
分享论文
